Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine

J Clin Oncol. 2022 Dec 1;40(34):3903-3906. doi: 10.1200/JCO.22.01406. Epub 2022 Sep 2.

Author

Gary K Schwartz¹

Affiliation

¹ Columbia University, New York, NY.

PMID: 36054848
DOI: 10.1200/JCO.22.01406

No abstract available

Publication types

Editorial
Comment

MeSH terms

Gastrointestinal Neoplasms* / drug therapy
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / pathology
Humans
Naphthyridines / therapeutic use
Precision Medicine
Urea

Substances

ripretinib
Naphthyridines
Urea